A service of

Samsung Biologics flexes M&A acumen with USD 2.2bn PolyPeptide takeover – Dealspeak APAC

A rising tide lifts all ships, and Samsung Biologics’ takeover of Swiss peptide manufacturer PolyPeptide is certainly giving the surging specialty drugs space and broader contract development & manufacturing origanisations (CDMO) sector a seminal M&A event they can hang their lab coats on.

Samsung Biologics is on track to complete its USD 2.2bn all-cash takeover of PolyPeptide by year-end or in 1Q27, subject to remaining regulatory approvals including Europe and India. The world’s largest biologics manufacturer by capacity last week successfully secured 97.98% of the target through its public tender offer, paving the way for a compulsory delisting and entry into the fast-growing peptide market.

The transaction marks Samsung Biologics’ largest-ever outbound M&A and a milestone for the CDMO sector. As one of the highest-multiple CDMO deals, it signals a shift towards consolidation as outsourced drug manufacturing increasingly moves beyond scale towards access to high-growth modalities and specialised technologies.

The race is heating up. Swiss rival Lonza announced  on 3 November the acquisition of CDMO assets from GSK for USD 427m, underscoring intensifying capacity expansion and M&A activity in the sector.

“The CDMO market is currently highly dynamic, and we see manufacturing sourcing as now a board topic as new modalities require significant investment,” said Daniel Mathew, partner and Global Life Science Sector Lead at Ernst & Young.

“CDMO competition is shifting toward qualified capacity, specialized capabilities, geographic resilience, and integrated multi-modality platforms, making M&A an increasingly important strategic lever,” he noted.

Winning auction for specialty platform 

Samsung Biologics’ acquisition of PolyPeptide followed an auction process involving global private equity firms, reportedly including EQT and IDG. Samsung Biologics began reviewing PolyPeptide in February this year when the Swiss company launched a strategic review through Morgan Stanley, as disclosed by Samsung’s regulatory filing in November.

The deal also marks one of Samsung Group’s rare overseas acquisitions of a publicly listed company since its USD 8.9bn takeover of US-based Harman in 2016, highlighting the nation’s largest conglomerate’s willingness to pursue strategic targets globally.

Beyond peptides, the platform provides Samsung Biologics with geographic diversification and a broader technology portfolio. The deal may represent only the opening move in a broader M&A strategy to build capabilities beyond traditional biologics into next-generation modalities, including ADCs, mRNA and cell and gene therapies.

Samsung’s tender offer price of CHF 44.31 per share values PolyPeptide’s equity at CHF 1.46bn and represents a 40% premium to the last unaffected closing price prior to deal speculation.

The transaction translates to an enterprise value (EV) equivalent to 4.94x revenue and 50.5x EBITDA based on PolyPeptide’s 2025 results, according to Mergermarket data. This is far higher than the median 3.77x revenue and 18.08x EBITDA across 588 global pharmaceutical CDMO deals (about 7% of deals with disclosed multiples) since 2021, tracked by this news service.

“I would see the valuation as reflecting the strategic value of differentiated capabilities rather than setting a new benchmark for the CDMO sector,” Mathews said. “Specialist expertise, established customer relationships and faster access to high-growth areas can all contribute to a premium valuation.”

The strategic significance also goes beyond adding manufacturing capacity, he added. “It reflects a broader shift in the CDMO market toward combining specialist capabilities, scale and geographic reach to build more integrated platforms.”

Samsung Biologics CEO also earlier remarked the acquisition will secure six sites and boost its “geographic reach and proximity further within the US, Europe, and India.”

Samsung Biologics derives about 90% of its revenue from overseas operations; Europe (52%) and the US (38%) as of 2025. The company, however, had relied solely on its manufacturing facilities in South Korea until March this year when it acquired a US asset in Maryland – GSK’s 60K litre (KL) biologics facility – bringing total biologic capacity to 845KL.

“More broadly, CDMO valuations are becoming increasingly bifurcated,” the partner at E&Y continued.

Differentiated niches such as peptides, ADCs, high-potency APIs, radiopharmaceuticals and specialised fill-finish operations can command substantial valuation premiums, whereas less differentiated manufacturing capacity is unlikely to attract similar multiples, he said.

PolyPeptide specialises in peptide therapeutics, a segment that has witnessed surging demand since 2025, driven by the growth of GLP-1 obesity and diabetes drugs and next-generation peptide-based medicines. Although PolyPeptide recorded loss-making until 2025, Samsung Biologics projects its revenue to grow at a CAGR of more than 10% between 2026 and 2031, with EBITDA margins exceeding 30% by 2031, as disclosed.

As drug development becomes more complex, outsourcing demand is expected to drive market growth from USD 28.4bn in 2026 to USD 43.9bn in 2029, a CAGR of 15.6%, according to Samsung’s disclosure citing Frost & Sullivan data.

Samsung Biologics meanwhile opted to finance the acquisition through a KRW 2.66tn (USD 1.9bn) rights issue “to preserve financial flexibility for future capex of its own and PolyPeptide,” as disclosed. The offering, backed by Samsung’s affiliates, was 97% subscribed, as announced yesterday (11 November).

Positioning for future deals 

The CDMO sector is expected to see more M&A activity amid increasing levels of competition as manufacturers seek to scale as well as specialized capabilities.

Only a handful of global peers had biologics capacity exceeding 300KL as of the end of 2025, including Samsung (845KL), Lonza (741KL), and WuXi Biologics (305KL), while FUJIFILM Biotechnologies’ capacity stood at 260KL, according to Samsung’s disclosure.

Lonza is among the industry’s most active acquirers, highlighted by its USD 5.5bn CDMO acquisition of Capsugel. 

“There is still meaningful room for bolt-on M&A,’’ said Mathews. “The CDMO market remains fragmented, particularly across specialized modalities, manufacturing steps, and geographies. Large CDMOs can continue to acquire specialist capabilities in areas such as peptides, ADCs, radiopharmaceuticals, high-potency APIs and sterile fill-finish,” he added.

Source: Companies, Samsung Biologics filings, data as of 2025 end